Home › Funds › Invenomic Capital Management LP › ENOV
Invenomic Capital Management LP position in ENOV
ENOVIS CORPORATION · Health Care
Invenomic Capital Management LP reported holding 1,120,699 shares of ENOV (ENOVIS CORPORATION) in its Q3 2026 13F filing — a position valued at US$20.5M, representing 1.01% of its reported portfolio and ranking #39 among its reported holdings. Invenomic Capital Management LP has disclosed ENOV holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Invenomic Capital Management LP's ENOV position evolved
Invenomic Capital Management LP first disclosed a stake in ENOV in Q4 2024 at 150,119 shares (US$6.6M). The position peaked in Q3 2025 at 712,669 shares, worth US$21.6M. Across 8 filings, Invenomic Capital Management LP increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,120,699 shares valued at US$20.5M — an increase of 348,665 shares quarter over quarter.. Notable position changes include a 200% increase in Q1 2025 (shares fell 18% over the following quarter), a 29% increase in Q2 2025 (shares fell 3% over the following quarter), a 45% increase in Q3 2026 (shares rose 53% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 150.12K | $6.59M | New |
| Q1 2025 | 449.78K | $17.19M | Add |
| Q2 2025 | 580.96K | $18.22M | Add |
| Q3 2025 | 712.67K | $21.62M | Add |
| Q4 2025 | 756.72K | $20.16M | Add |
| Q1 2026 | 903.46K | $20.55M | Add |
| Q2 2026 | 772.03K | $15.98M | Reduce |
| Q3 2026 | 1.12M | $20.48M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ENOV and 13F data
ENOV (ENOVIS CORPORATION) is a Health Care company. 19 other funds we track also report a position in ENOV — the largest reported positions include Rubric Capital Management LP (US$96.8M), OAKTREE CAPITAL MANAGEMENT LP (US$37.8M), PRIVATE MANAGEMENT GROUP INC (US$32.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ENOV
- Rubric Capital Management LP 5.30M sh · $96.83M · Q3 2026
- OAKTREE CAPITAL MANAGEMENT LP 39.21M sh · $37.79M · Q2 2026
- PRIVATE MANAGEMENT GROUP INC 1.79M sh · $32.75M · Q3 2026
- PARADIGM CAPITAL MANAGEMENT INC/NY 1.66M sh · $30.26M · Q3 2026
- Front Street Capital Management, Inc. 1.45M sh · $26.48M · Q3 2026
- ARISTEIA CAPITAL, L.L.C. 25.43M sh · $24.17M · Q3 2026
More on Invenomic Capital Management LP
FAQ
How long has Invenomic Capital Management LP held ENOV?
Invenomic Capital Management LP has disclosed ENOV holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Invenomic Capital Management LP's current position in ENOV?
As of Q3 2026, Invenomic Capital Management LP holds 1.12M shares of ENOV (ENOVIS CORPORATION), valued at $20.48M, representing 1.01% of its reported portfolio and ranking #39.
Has Invenomic Capital Management LP been buying or selling ENOV?
In the latest 13F filing (Q3 2026), Invenomic Capital Management LP increased its position in ENOV. The position peaked in Q3 2025 at 712.67K shares.
Which other funds hold ENOV?
Other major institutional holders of ENOV include Rubric Capital Management LP, OAKTREE CAPITAL MANAGEMENT LP, PRIVATE MANAGEMENT GROUP INC, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.